Abstract
Recent evidence has associated the aberrant, proximal re-expression of various cell cycle control elements with neuronal cell vulnerability in Alzheimers and Parkinsons diseases, as a common chronic neurodegeneration. This phenomenon associated with oncogenic transduction pathways activation has attracted the interest of scientists all over the world for a few years now. The purpose of this paper is to outline areas of research related to oncogenic factors or medicines in the context of potential applications for future treatment of the above mentioned chronic and, largely, incurable diseases.
Keywords: Alzheimer's disease, Parkinson's disease, oncogenes, cell cycle, mitochondria
CNS & Neurological Disorders - Drug Targets
Title: Implication of Oncogenic Signaling Pathways as a Treatment Strategy for Neurodegenerative Disorders – Contemporary Approaches
Volume: 10 Issue: 2
Author(s): Adrian Sieradzki, Bharat B. Yendluri, Hector H. Palacios, Kalpana Parvathaneni, V. Prakash Reddy, Mark E. Obrenovich, Kazimierz Gasiorowski, Jerzy Leszek and Gjumrakch Aliev
Affiliation:
Keywords: Alzheimer's disease, Parkinson's disease, oncogenes, cell cycle, mitochondria
Abstract: Recent evidence has associated the aberrant, proximal re-expression of various cell cycle control elements with neuronal cell vulnerability in Alzheimers and Parkinsons diseases, as a common chronic neurodegeneration. This phenomenon associated with oncogenic transduction pathways activation has attracted the interest of scientists all over the world for a few years now. The purpose of this paper is to outline areas of research related to oncogenic factors or medicines in the context of potential applications for future treatment of the above mentioned chronic and, largely, incurable diseases.
Export Options
About this article
Cite this article as:
Sieradzki Adrian, B. Yendluri Bharat, H. Palacios Hector, Parvathaneni Kalpana, Prakash Reddy V., E. Obrenovich Mark, Gasiorowski Kazimierz, Leszek Jerzy and Aliev Gjumrakch, Implication of Oncogenic Signaling Pathways as a Treatment Strategy for Neurodegenerative Disorders – Contemporary Approaches, CNS & Neurological Disorders - Drug Targets 2011; 10 (2) . https://dx.doi.org/10.2174/187152711794480410
DOI https://dx.doi.org/10.2174/187152711794480410 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
25OH-Vitamin D3 Levels in Obesity and Metabolic Syndrome—Unaltered in Young and not Correlated to Carotid IMT in All Ages
Current Pharmaceutical Design Importance of Dietary Supplements to the Health
Current Nutrition & Food Science VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets The Metabolic Rationale for a Lack of Cross-reactivity Between Sulfonamide Antimicrobials and Other Sulfonamide-containing Drugs
Drug Metabolism Letters Neovascular Age-Related Macular Degeneration and its Association with Alzheimer’s Disease
Current Aging Science Views on Amyloid Hypothesis and Secretase Inhibitors for Treating Alzheimers Disease: Progress and Problems
Current Pharmaceutical Design The Therapeutical Potential of Alpha-Synuclein Antiaggregatory Agents for Dementia with Lewy Bodies
Current Medicinal Chemistry Pharmacotherapy Before and After Endovascular Repair of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Guggulsterone for Chemoprevention of Cancer
Current Pharmaceutical Design Preface: (Commentary on the Special Issue on the Impact of Myogenic Tone in Health and Disease)
Current Vascular Pharmacology From Stem Cells to Dopamine Neurons: Developmental Biology Meets Neurodegeneration
CNS & Neurological Disorders - Drug Targets Ajmalicine and its Analogues Against AChE and BuChE for the Management of Alzheimer’s Disease: An <i>In-silico</i> Study
Current Pharmaceutical Design Histone Deacetylase (HDAC) Inhibitors as Potential Drugs to Target Memory and Adult Hippocampal Neurogenesis
Current Psychopharmacology Association Study of 10 Candidate Genes with Sporadic Alzheimers Disease in a Spanish Population
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents DLPF Targeted Repetitive Transcranial Magnetic Stimulation Improves Brain Glucose Metabolism Along with the Clinical and Electrophysiological Parameters in CBD Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Association between Periodontal Health Status and Cognitive Abilitie s. The Role of Cytokine Profile and Systemic Inflammation
Current Alzheimer Research Editorial [Hot Topic:Nicotinamide Adenine Dinucleotide Biology and Disease(Executive Editor: W. Todd Penberthy)]
Current Pharmaceutical Design Early Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Current Genomics On Chemical Structures with Potent Antiepileptic/Anticonvulsant Profile
Mini-Reviews in Medicinal Chemistry Meet Our Associate Editor
Central Nervous System Agents in Medicinal Chemistry